| Date | Title | | | 03/09/10 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth
Quarter and Year Ended December 31, 2009| SAN DIEGO, Mar 09, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its financial results for the fourth quarter and year
ended December 31, 2009.
ACADIA reported a net loss of $8.7 million, or $0.23 per common share,
for the fourth quarter of 2009 compared t... |
|  | | 03/02/10 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2009
Financial Results on March 9, 2010| ACADIA to Host Conference Call and Webcast on Tuesday, March 9, 2010, at 5:00 p.m. Eastern TimeSAN DIEGO, Mar 02, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the fourth quarter and year ended December 31, 2... |
| | | 02/01/10 | ACADIA Pharmaceuticals to Present at the BIO CEO & Investor
Conference on February 8, 2010| SAN DIEGO, Feb 01, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the BIO CEO & Investor
Conference 2010 on Monday, February 8, 2010, at 3:00 p.m. Eastern Time
at The Waldorf=Astoria Hotel in New York City.
A live webcast of ACA... |
| | | 11/09/09 | ACADIA Pharmaceuticals Reports Third Quarter 2009 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Nov. 9, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the third quarter
ended September 30, 2009.
ACADIA reported a net loss of $8.7 million, or $0.23 per common share,
for the third quarte... |
| | | 11/02/09 | ACADIA Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 9, 2009|
ACADIA to Host Conference Call and Webcast on Monday, November 9,
2009, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Nov. 2, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the third quar... |
| | | 10/20/09 | ACADIA Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26, 2009| SAN DIEGO--(BUSINESS WIRE)--Oct. 20, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the BIOCOM Investor Conference
2009 on Monday, October 26, 2009 at 2:30 p.m. Pacific Time at the Hyatt
Regency in San Diego.
A live webcast of AC... |
| | | 10/06/09 | ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2009| SAN DIEGO--(BUSINESS WIRE)--Oct. 6, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the JMP Securities Healthcare
Focus Conference on Tuesday, October 6, 2009 at 3:00 p.m. Eastern Time
at The New York Palace Hotel in New York City.
... |
| | | 10/06/09 | ACADIA Pharmaceuticals Provides Update on Pimavanserin Collaborative Development Program| SAN DIEGO--(BUSINESS WIRE)--Oct. 6, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today provided an update on its Phase III program with pimavanserin for
Parkinson’s disease psychosis (PDP), which is being pursued in
collaboration with Biovail Laboratories International SRL (&... |
| | | 09/01/09 | ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis|
Pimavanserin Misses Primary Endpoint of Antipsychotic Efficacy; Meets
Key Secondary Endpoint of Motoric Tolerability
Conference Call Scheduled for Today, September 1, at 8:00 A.M.
Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Sep. 1, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line
results from the first pivotal Phase III trial with pimavanserin in
patients with Parkinson’s disease psychosis, or P... |
| | | 08/05/09 | ACADIA Pharmaceuticals Reports Second Quarter 2009 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Aug. 5, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the second quarter
and six months ended June 30, 2009.
ACADIA reported a net loss of $12.7 million, or $0.34 per common share,
for the ... |
| | | 07/29/09 | ACADIA Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 5, 2009| ACADIA to Host Conference Call and Webcast on Wednesday, August 5, 2009, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Jul. 29, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the second quarter ended June 30, 20... |
| | | 06/03/09 | ACADIA Pharmaceuticals to Present at the Eighth Annual Needham Life Sciences Conference on June 10, 2009| SAN DIEGO--(BUSINESS WIRE)--Jun. 3, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Eighth Annual Needham Life
Sciences Conference on Wednesday, June 10, 2009 at 9:30 a.m. Eastern
Time at The New York Palace Hotel in New York City.
... |
| | | 05/13/09 | ACADIA Pharmaceuticals to Present at the Eighth Annual JMP Securities Research Conference on May 19, 2009| SAN DIEGO--(BUSINESS WIRE)--May. 13, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Eighth Annual JMP Securities
Research Conference on Tuesday, May 19, 2009 at 2:30 p.m. Pacific Time
at The Ritz-Carlton Hotel in San Francisco.
... |
| | | 05/11/09 | ACADIA Pharmaceuticals Reports First Quarter 2009 Financial Results| SAN DIEGO--(BUSINESS WIRE)--May. 11, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the first quarter
ended March 31, 2009.
ACADIA reported a net loss of $15.0 million, or $0.40 per common share,
for the first quarter ... |
| | | 05/06/09 | ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis| Top-Line Data Expected in the Third Quarter of 2009
SAN DIEGO & TORONTO--(BUSINESS WIRE)--May. 6, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) and Biovail Corporation
(NYSE:BVF) (TSX:BVF), today announced the completion of enrollment in
the first pivotal Phase III clinical trial of pimavanserin in patients
with Parkinson’s disease psychosis (PDP). Top-line results from this
trial are expected to be announced by the end of the third quarter of
20... |
| | | 05/05/09 | ACADIA Pharmaceuticals to Announce First Quarter 2009 Financial Results on May 11, 2009| ACADIA to Host Conference Call and Webcast on Monday, May 11, 2009, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--May. 5, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the first quarter ended March 31, 2009 on... |
| | | 05/04/09 | ACADIA Pharmaceuticals and Biovail Form Collaboration to Develop and Commercialize Pimavanserin in North America| Conference Call Scheduled for Today, May 4, 2009, at 8:30 a.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--May. 4, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) today announced that it has
established a collaboration with Biovail Laboratories International SRL,
a subsidiary of Biovail Corporation, to co-develop and commercialize
pimavanserin, ACADIA’s proprietary and selective 5-HT2A inverse
agonist, in the United States and Canada. ACADIA retains rights t... |
| | | 03/25/09 | ACADIA Pharmaceuticals and Meiji Seika Kaisha Form Collaboration to Develop and Commercialize a New Class of Pro-Cognitive Schizophrenia Drugs| Meiji Seika Granted Rights to Develop and Commercialize Products in Asian Territory; ACADIA Retains All Rights in the Rest of the World
SAN DIEGO--(BUSINESS WIRE)--Mar. 25, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) and Meiji Seika Kaisha, Ltd.
(TSE:2202) today announced that they have established a collaboration to
develop and commercialize a novel class of pro-cognitive drugs to treat
patients with schizophrenia and related disorders in Japan and several
... |
| | | 03/09/09 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2008| SAN DIEGO--(BUSINESS WIRE)--Mar. 9, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the fourth quarter
and year ended December 31, 2008.
ACADIA reported a net loss of $14.0 million, or $0.38 per common share,
for the fo... |
| | | 03/04/09 | ACADIA Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference on March 11, 2009| SAN DIEGO--(BUSINESS WIRE)--Mar. 4, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Barclays Capital Global
Healthcare Conference on Wednesday, March 11, 2009, at 9:30 a.m. Eastern
Time at the Loews Miami Beach Hotel in Miami Beach, Florida.... |
| | | 03/02/09 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009| ACADIA to Host Conference Call and Webcast on Monday, March 9, 2009, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Mar. 2, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the fourth quarter and year ended Decemb... |
| | | 02/03/09 | ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 10, 2009| SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the BIO CEO & Investor
Conference 2009 on Tuesday, February 10, 2009, at 10:00 a.m. Eastern
Time at The Waldorf=Astoria Hotel in New York City.
A live webcast o... |
| | | 01/07/09 | ACADIA Pharmaceuticals Awarded Grant from The Michael J. Fox Foundation for the Development of Novel ER-beta Agonists for the Treatment of Parkinson’s Disease| SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it has been awarded a grant from The Michael J. Fox
Foundation for the development of novel estrogen receptor beta (ER-beta)
agonists for the treatment of Parkinson’s disease. The grant of up to
... |
| | | 11/25/08 | ACADIA Pharmaceuticals to Present at The 20th Annual Piper Jaffray Health Care Conference on December 3, 2008| SAN DIEGO, Nov 25, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at The 20th Annual Piper
Jaffray Health Care Conference on Wednesday, December 3, 2008, at 10:30
a.m. Eastern Time at The New York Palace Hotel in New York City.
A live ... |
| | | 11/05/08 | ACADIA Pharmaceuticals Reports Third Quarter 2008 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Nov. 5, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today reported its
unaudited financial results for the third quarter ended September 30,
2008.
ACADIA reported a net loss of $15.6 million, or $0.42 per common
share, for the third quarter of 2008 compared to a net loss of $16.0
mil... |
| | | 11/03/08 | ACADIA Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11, 2008| SAN DIEGO--(BUSINESS WIRE)--Nov. 3, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at The Rodman & Renshaw 10th Annual Healthcare
Conference on Tuesday, November 11, 2008, at 11:35 a.m. Eastern Time
at The New York Palace Hotel in New York City.
A live webcast of ACADIA's presen... |
| | | 10/29/08 | ACADIA Pharmaceuticals to Announce Third Quarter 2008 Financial Results on November 5, 2008| ACADIA to Host Conference Call and Webcast on Wednesday, November
5, 2008, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the third quarter
ended September 30, 2008... |
| | | 10/21/08 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that it will present at the following
investor conferences:
-- The BIOCOM Investor Conference 2008 on Tuesday, October 28,
2008, at 3:30 p.m. Pacific Time at the Hyatt Regency in San
Diego.
-- BIO I... |
| | | 09/29/08 | ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2008| SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that it will present at the JMP Securities
Healthcare Focus Conference on Monday, October 6, 2008, at 1:00 p.m.
Eastern Time at Le Parker Meridien Hotel in New York City.
A live webcast of ACADIA's presentation will be accessible o... |
| | | 09/05/08 | ACADIA Pharmaceuticals Files Registration Statement as Required by Previously Announced Committed Equity Financing Facility| SAN DIEGO--(BUSINESS WIRE)--Sept. 5, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it filed a registration statement as required under the terms of its
previously announced Committed Equity Financing Facility (CEFF) with
Kingsbridge Capital Limited.
Under the terms of the CEFF, ACADIA has acces... |
| | | 08/28/08 | ACADIA Pharmaceuticals to Present at The Thomas Weisel Partners Healthcare Conference on September 4, 2008| SAN DIEGO, Aug 28, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at The Thomas Weisel Partners 2008
Healthcare Conference on Thursday, September 4, 2008, at 2:40 p.m.
Eastern Time at the Four Seasons Boston Hotel.
A live webcast of AC... |
| | | 08/05/08 | ACADIA Pharmaceuticals Secures Committed Equity Financing Facility| SAN DIEGO, Aug 05, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that it has entered into a Committed Equity
Financing Facility (CEFF) with Kingsbridge Capital Limited in which
Kingsbridge has committed to provide up to $60 million of capital
during the next three years through the purchase... |
| | | 08/05/08 | ACADIA Pharmaceuticals Announces Second Quarter 2008 Financial Results and Strategic Restructuring| SAN DIEGO--(BUSINESS WIRE)--Aug. 5, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today reported its
unaudited financial results for the second quarter ended June 30, 2008
and announced a strategic restructuring.
ACADIA will focus on developing a portfolio of its four most
advanced product candidates, consisting o... |
| | | 07/29/08 | ACADIA Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008| ACADIA to Host Conference Call and Webcast on Tuesday, August 5,
2008, at 8:30 a.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--July 29, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the second quarter
ended June 30, 2008 on... |
| | | 06/16/08 | ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial| -- Conference Call Scheduled for Today, June 16, 2008, at 8:30
a.m. Eastern Time --
SAN DIEGO--(BUSINESS WIRE)--June 16, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD) today announced results from its Phase IIb trial
with ACP-104 for the treatment of schizophrenia. The study did not
meet its primary endpoint of antipsychotic efficacy or any of the
secondary endpoints. Neither dose of ACP-104 demonstrated improved
efficacy as compared to placebo. The most c... |
| | | 06/04/08 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--June 4, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the following investor conferences:
The Seventh Annual Needham & Company Biotechnology and Medical
Technology Conference on Wednesday, June 11, 2008, at 1:30
p.m. Eastern Time at ... |
| | | 05/14/08 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--May 14, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the following investor conferences:
The 2008 Citi Investment Research Global Health Care
Conference on Thursday, May 22, 2008, at 10:30 a.m. Eastern
Time at the Hilton New York i... |
| | | 05/05/08 | ACADIA Pharmaceuticals Announces Election of Laura A. Brege to Board of Directors| SAN DIEGO--(BUSINESS WIRE)--May 5, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced the
election of Laura A. Brege to its board of directors. Ms. Brege will
fill a vacancy on the Board and serve as a Class III director. The
terms of the Class III directors expire at the annual meeting of
stockholders in 2... |
| | | 05/05/08 | ACADIA Pharmaceuticals Reports First Quarter 2008 Financial Results| SAN DIEGO--(BUSINESS WIRE)--May 5, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system (CNS) disorders, today reported
its unaudited financial results for the first quarter ended March 31,
2008.
ACADIA reported a net loss of $16.4 million, or $0.44 per common
share, for the first quarter of 2008 compared to a net loss of $12.6
mil... |
| | | 04/30/08 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--April 30, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the following investor conferences:
Deutsche Bank's 33rd Annual Health Care Conference on
Wednesday, May 7, 2008, at 9:30 a.m. Eastern Time at the
InterContinental Boston Hote... |
| | | 04/28/08 | ACADIA Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 5, 2008| ACADIA to Host Conference Call and Webcast on Monday, May 5, 2008,
at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--April 28, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the first quarter
ended March 31, 2008 on M... |
| | | 04/16/08 | ACADIA Pharmaceuticals to Present Data from Its Phase II Trial with Pimavanserin for Parkinson's Disease Psychosis at the 60th American Academy of Neurology Annual Meeting| SAN DIEGO--(BUSINESS WIRE)--April 16, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
the company will present data from its previously reported Phase II
trial with pimavanserin for Parkinson's disease psychosis (PDP) at the
60th American Academy of Neurology Annual Meeting on April 16, 2008 in
Chica... |
| | | 04/04/08 | ACADIA Pharmaceuticals to Present Preclinical Data on ACP-104, ACP-105 and Its Muscarinic Discovery Program at Experimental Biology 2008 Meeting| SAN DIEGO--(BUSINESS WIRE)--April 4, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
the company will present preclinical data on its ACP-104 schizophrenia
program, its ACP-105 Selective Androgen Receptor Modulator (SARM)
program, and its muscarinic discovery program at the Experimental
Biology 2008... |
| | | 03/31/08 | ACADIA Pharmaceuticals Initiates Second Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis| SAN DIEGO--(BUSINESS WIRE)--March 31, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it has initiated its second Phase III trial designed to evaluate the
safety and efficacy of pimavanserin as a treatment for Parkinson's
disease psychosis (PDP).
"The start of our second Phase III pivotal trial r... |
| | | 03/28/08 | ACADIA Pharmaceuticals to Present at the 8th Annual Fortis Bank Biotechnology Conference| SAN DIEGO, Mar 28, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that it will present at The 8th Annual
Fortis Bank Biotechnology Conference on Thursday, April 3, 2008, at
10:00 a.m. Western European Time at the Four Seasons Hotel London in
London, England.
About ACADIA Pharmaceuticals
... |
| | | 03/11/08 | ACADIA Pharmaceuticals to Present at Lehman Brothers 11th Annual Global Healthcare Conference| SAN DIEGO--(BUSINESS WIRE)--March 11, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at Lehman Brothers 11th Annual Global Healthcare
Conference on Tuesday, March 18, 2008, at 2:00 p.m. Eastern Time at
the Loews Miami Beach Hotel in Miami Beach, Florida.
A live webcast of ACADIA... |
| | | 03/05/08 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007|
SAN DIEGO--(BUSINESS WIRE)--March 5, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD),
a biopharmaceutical company utilizing innovative technology to fuel drug discovery
and clinical development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the fourth quarter and year
ended December 31, 2007.
ACADIA reported a net loss of $17.0 million, or $0.46 per common share, for
the fourth quarter of 2007 compared to a n... |
| | | 02/27/08 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 5, 2008| ACADIA to Host Conference Call and Webcast on Wednesday, March 5,
2008, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Feb. 27, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the fourth quarter
and year ended December ... |
| | | 02/12/08 | ACADIA Pharmaceuticals Appoints John J. Kaiser as Vice President, Strategic Marketing and Commercial Development| SAN DIEGO, Feb 12, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced the appointment of John J. Kaiser as Vice
President, Strategic Marketing and Commercial Development. Mr. Kaiser
joins ACADIA from Eli Lilly & Co. where he held a variety of marketing
and commercial management positions over a... |
| | | 02/05/08 | ACADIA Pharmaceuticals Announces Presentation of Data on Pimavanserin Co-Therapy at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders| New Data Demonstrate Less Increase in Serum Glucose Levels With Pimavanserin Co-Therapy
SAN DIEGO, Feb 05, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that Murray Rosenthal, D.O., a Fellow of
the American Psychiatric Association, will present data from ACADIA's
pimavanserin Phase II schiz... |
| | | 02/04/08 | ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2008| SAN DIEGO, Feb 04, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that it will present at the BIO CEO &
Investor Conference 2008 on Tuesday, February 12, 2008, at 10:15 a.m.
Eastern Time at The Waldorf=Astoria Hotel in New York City.
A live webcast of ACADIA's presentation will be accessible... |
| |
|
